patient subgroup...
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
interferon - versus standard of care - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 2.45 [0.21, 28.37]< 1 0% 2 studies (3/-) 23.8 % some concern not evaluable moderate crucial - deaths 0.47 [0.22, 1.02]< 1 0% 6 studies (8/-) 97.2 % some concern not evaluable moderate crucial - deaths (time to event analysis only) 0.38 [0.16, 0.87]< 1 0% 1 study (1/-) 98.8 % NA not evaluable crucial - clinical deterioration 2.29 [0.20, 26.58]< 1 0% 1 study (1/-) 25.6 % NA not evaluable important - clinical improvement 1.37 [0.41, 4.61]> 1 67% 2 studies (3/-) 69.6 % some concern not evaluable moderate important - clinical improvement (14-day) 2.03 [0.17, 24.32]> 1 75% 2 studies (2/-) 71.0 % some concern not evaluable moderate important - clinical improvement (7-day) 1.91 [1.03, 3.53]> 1 0% 1 study (1/-) 98.0 % NA not evaluable important - clinical improvement (time to event analysis only) 2.17 [1.34, 3.51]> 1 0% 3 studies (4/-) 99.9 % some concern not evaluable moderate important - hospital discharge 3.44 [0.64, 18.49]> 1 0% 1 study (2/-) 92.4 % NA not evaluable important - mechanical ventilation 0.75 [0.34, 1.69]< 1 0% 3 studies (4/-) 75.5 % some concern not evaluable moderate important - viral clearance 2.69 [1.48, 4.87]> 1 0% 2 studies (3/-) 99.9 % some concern not evaluable moderate important - viral clearance (time to event analysis only) 3.26 [1.53, 6.95]> 1 0% 1 study (1/-) 99.9 % NA not evaluable important - viral clearance by day 14 0.18 [0.00, 435.69]> 1 98% 2 studies (3/-) 34.4 % some concern not evaluable moderate important - viral clearance by day 7 2.69 [1.48, 4.87]> 1 0% 2 studies (3/-) 99.9 % some concern not evaluable moderate important - ICU admission 0.49 [0.24, 1.00]< 1 0% 3 studies (3/-) 97.4 % some concern not evaluable moderate non important - off oxygenation 8.57 [1.43, 51.36]> 1 0% 1 study (1/-) 99.0 % NA not evaluable non important - safety endpoints 00 serious adverse events 0.95 [0.02, 50.33]< 1 0% 1 study (1/-) 51.0 % NA not evaluable important - superinfection 0.18 [0.02, 1.59]< 1 0% 1 study (2/-) 93.8 % NA not evaluable important - adverse events 1.68 [0.47, 5.97]< 1 0% 1 study (2/-) 21.1 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.